Pharmaceuticals

Recently, Novartis AG (NVS) presented data from the AZURE trial of its bone drug Zometa at the annual Antonio Breast Cancer Symposium. The phase III study tested the effectiveness of Zometa in improving disease free survival in both premenopausal and postmenopausal women with early breast cancer...

Jumped into Viropharma (VPHM) this morning at $17.11 on a break of previous highs, which it did in a very convincing manner. To say the least I am glad I got in when I did, though it is impossible to know that a stock will pop its top like it did soon after I got in.  Here's the chart setup on VPHM...

Cubist Pharmaceuticals Inc. (CBST) recently lowered its revenue outlook for 2010 due to continuing softness in US sales of its only marketed antibiotic Cubicin. The company now expects to generate revenue in the range of $634–$640 million in fiscal 2010, down from a previous range of $645–$650...

Cubist Pharmaceuticals Inc. (CBST) recently lowered its revenue outlook for 2010 due to continuing softness in US sales of its only marketed antibiotic Cubicin. The company now expects to generate revenue in the range of $634–$640 million in fiscal 2010, down from a previous range of $645–$650...

• Joy Global (NASDAQ:JOYG) reported fiscal fourth quarter earnings of $1.39, ahead of the Zacks Consensus Estimate of $1.16, on revenues of $1.05 billion that topped the Zacks Consensus Estimate of $925.0 million. The firm provided upside 2011 guidance of $5.00-$5.30, above the Zacks Consensus...

Cypress Bioscience Inc (NASDAQ: CYPB) shares gained 12.17% to create a new 52-week high of $6.45. CYPB agreed to be purchased by Ramius V&O Acquisition LLC and affiliates of Royalty Pharma for $6.50 per share in cash. G&K Services Inc (NASDAQ: GKSR) shares jumped 1.86% to touch a new 52-...

Akorn (NASDAQ: AKRX) is trading substantially higher today. At last check, AKRX is trading at $5.80, up 8.82% from yesterday.

• Joy Global (NASDAQ:JOYG) reported fiscal fourth quarter earnings of $1.39, ahead of the Zacks Consensus Estimate of $1.16, on revenues of $1.05 billion that topped the Zacks Consensus Estimate of $925.0 million. The firm provided upside 2011 guidance of $5.00-$5.30, above the Zacks Consensus...

Atrinsic Inc (NASDAQ: ATRND) jumped 30.63% to $2.90 at 10:00 am. ATRND had $4.25 million in total cash and no debt for the latest quarter. Rainmaker Systems Inc (NASDAQ: RMKR) climbed 16.95% to $1.38. RMKR's shares have dipped 16.31% over the past 52 weeks, while the S&P 500 index has gained 12...

Unconfirmed Rumors circulate that GlaxoSmithKline plc (GSK) will acquire Human Genome Sciences Inc. (HGSI) at $42.00 a share.

On Tuesday, the markets closed almost flat after a muted view from the Federal Reserve about the economic recovery. However, stocks were helped marginally by the positive report on retail spending.   The Dow Jones Industrial Average rose 0.4% to 11,476.54.The Standard & Poor's 500 was up 0.1%...

Johnson & Johnson (NYSE: JNJ) today announced that Alex Gorsky, currently Worldwide Chairman, Medical Devices & Diagnostics and Sheri McCoy, currently Worldwide Chairman, Pharmaceuticals, have been appointed Vice Chairmen of the Executive Committee and join William C. Weldon, Chairman of...

On Tuesday, the markets closed almost flat after a muted view from the Federal Reserve about the economic recovery. However, stocks were helped marginally by the positive report on retail spending.   The Dow Jones Industrial Average rose 0.4% to 11,476.54.The Standard & Poor's 500 was up 0.1%...

Cypress Bioscience Inc (NASDAQ: CYPB) rose 12.87% to $6.49 in the pre-market session. CYPB has agreed to be purchased by Ramius V&O Acquisition LLC and affiliates of Royalty Pharma for $6.50 per share in cash. Joy Global Inc (NASDAQ: JOYG) added 5.35% to $84.50 in the pre-market session. JOYG...

Cypress Bioscience, Inc. (Nasdaq: CYPB) announced today that it has entered into a definitive merger agreement with Ramius V&O Acquisition LLC, an affiliate of Ramius LLC and affiliates of Royalty Pharma, providing for the acquisition of Cypress by Ramius and Royalty Pharma. Under the terms of...